Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 25, 2016 - Issue 5
Submit an article Journal homepage
1,249
Views
34
CrossRef citations to date
0
Altmetric
Drug Evaluation

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer

S. Percy IvyCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USACorrespondence[email protected]
,
Joyce F. LiuGynecologic Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA
,
Jung-Min LeeCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA
,
Ursula A. MatulonisGynecologic Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA
&
Elise C. KohnCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
Pages 597-611 | Received 23 Oct 2015, Accepted 17 Feb 2016, Published online: 16 Mar 2016

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.